The significance of early diagnosis of cancer-related hypercalcaemia;Malignitáshoz társuló hypercalcaemia korai felismerésének jelentosége

Orvosi Hetilap

Volumn 154, Issue 35, 2013, Pages 1367-1373

  Radványi, Ildikó ^a   Csikós, Ágnes ^a   Balogh, Sándor ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

bisphosphonates; cancer related hypercalcaemia; quality of life; symptomatic treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; SODIUM CHLORIDE;

ARTICLE; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CANCER PALLIATIVE THERAPY; DIAGNOSTIC ERROR; DISEASE COURSE; EARLY DIAGNOSIS; HOSPITAL PATIENT; HUMAN; HUMORAL HYPERCALCEMIA; HYPERCALCEMIA; KIDNEY TUBULE; NEOPLASM; OSTEOCLAST; OSTEOLYSIS; OSTEOLYTIC HYPERCALCAEMIA;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC ERRORS; DIPHOSPHONATES; EARLY DIAGNOSIS; FLUID THERAPY; GALLIUM; HUMANS; HYPERCALCEMIA; INCIDENCE; NEOPLASMS; OSTEOLYSIS; PALLIATIVE CARE; PREVALENCE; RANK LIGAND;

EID: 84883378673     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29665     Document Type: Article

References (44)

1. Frølich, A.: Prevalence of hypercalcemia in normal and in hospital patients. Dan. Med. Bull., 1998, 45, 436-439. (Pubitemid 28419433)
2. Lamy, O., Jenzer-Closuit, A., Burckhardt, P.: Hypercalcaemia of malignancy: an undiagnosed and undertreated disease. J. Intern. Med., 2001, 250, 73-79. (Pubitemid 34208941)
3. Stewart, A. F.: Clinical practice. Hypercalcemia associated with cancer. N. Engl. J. Med., 2005, 352, 373-379.
4. Vassilopoulou-Sellin, R., Newmann, B. M., Taylor, S. H., et al.: Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer, 1993, 71, 1309-1312. (Pubitemid 23054924)
5. Pecherstorfer, M., Schilling, T., Blind, E., et al.: Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J. Clin. Endocrinol. Metab., 1994, 78, 1268-1270.
6. Walker, P. W.: Cancer-related syndromes. In: Walsh, D. (ed.): Palliative medicine. Saunders, Philadelphia, 2009, 1282-1285.
7. Suva, L. J., Winslow, G. A., Wettenhall, R. E., et al.: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science, 1987, 237, 893-896. (Pubitemid 17128278)
8. Horiuchi, N., Caulfield, M. P., Fischer, J. E., et al.: Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science, 1987, 238, 1566-1568. (Pubitemid 18032471)
9. Heys, S. D., Smith, I. C., Eremin, O.: Hypercalcaemia in patients with cancer: aetiology and treatment. Eur. J. Surg. Oncol., 1998, 24, 139-142. (Pubitemid 28205944)
10. Lumachi, F., Brunello, A., Roma, A., et al.: Cancer-induced hypercalcemia. Anticancer Research, 2009, 29, 1551-1555.
11. Clines, G. A., Guise, T. A.: Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr. Relat. Cancer, 2005, 12, 549-583. (Pubitemid 41482993)
12. Budayr, A. A., Nissenson, R. A., Klein, R. F., et al.: Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann. Intern. Med., 1989, 111, 807-812. (Pubitemid 19283917)
13. Burtis, W. J., Brady, T. G., Orloff, J. J., et al.: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N. Engl. J. Med., 1990, 322, 1106-1112. (Pubitemid 20149527)
14. Quinn, J. M., Matsumura, Y., Tarin, D., et al.: Cellular and hormonal mechanisms associated with malignant bone resorption. Lab. Invest., 1994, 71, 465-471. (Pubitemid 24338153)
15. Solimando, D. A.: Overview of hypercalcemia of malignancy. Am. J. Health Syst. Pharm., 2001, 58 (Suppl. 3), S4-S7. (Pubitemid 33062554)
16. Heged?s, K.: Disorders of calcium homeostasis. Fundamentals of palliative treatment. [A kalciumháztartás zavarai. A palliatív ellátás alapjai.] Semmelweis Kiadó, Budapest, 2009, 78-80. [Hungarian]
17. National Cancer Institute: PDQ® Hypercalcaemia. National Cancer Institute, Bethesda, MD. Available at: . Accessed: April 3, 2013.
18. Bajorunas, D. R.: Clinical manifestations of cancer-related hypercalcemia. Semin. Oncol., 1990, 17 (Suppl. 5), 16-25. (Pubitemid 20171904)
19. Mahon, S. M.: Signs and symptoms associated with malignancy-induced hypercalcemia. Cancer Nurs., 1989, 12, 153-160. (Pubitemid 19197859)
20. LeGrand, S. B., Leskuski, D., Zama, I.: Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann. Intern. Med., 2008, 149, 259-263.
21. Rogers, M. J.: New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des., 2003, 9, 2643-2658. (Pubitemid 37456015)
22. Rodan, G. A., Reszka, A. A.: Bisphosphonate mechanism of action. Curr. Mol. Med., 2002, 2, 571-577. (Pubitemid 34982189)
23. Nagykálnai, T.: Bisphosphonates in the treatment of bone metastases. [Biszfoszfonátok a daganatos csontáttétek kezelésében.] LAM, 2007, 17, 195-201. [Hungarian]
24. Body, J. J.: Treatment and prevention of bone metastases and myeloma bone disease. In: Rosen, C. J. (ed.): Primer on the metabolic bone diseases and disorders of mineral metabolism. Am. Society for Bone and Mineral Research, Washington, 2006, 383-390.
25. Ralston, S. H.: Medical management of hypercalcaemia. Br. J. Clin. Pharmacol., 1992, 34, 11-20.
26. Major, P., Lortholary, A., Hon, J., et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J. Clin. Oncol., 2001, 19, 558-567. (Pubitemid 32112871)
27. Berenson, J. R.: Treatment of hypercalcemia of malignancy with bisphosphonates. Semin. Oncol., 2002, 29 (Suppl. 21), 12-18. (Pubitemid 36222938)
28. Rosen, L. S., Gordon, D., Kaminski, M., et al.: Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98, 1735-1744. (Pubitemid 37238631)
29. Ralston, S. H., Thiébaud, D., Herrmann, Z., et al.: Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br. J. Cancer, 1997, 75, 295-300. (Pubitemid 27019577)
30. Pecherstorfer, M., Herrmann, Z., Body, J. J., et al.: Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J. Clin. Oncol., 1996, 14, 268-276. (Pubitemid 26020023)
31. Pecherstorfer, M., Steinhauer, E. U., Rizzoli, R., et al.: Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support. Care Cancer, 2003, 11, 539-547. (Pubitemid 36994438)
32. Santini, D., Vespasiani Gentilucci, U., Vincenzi, B., et al.: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann. Oncol., 2003, 14, 1468-1476. (Pubitemid 37304600)
33. Zojer, N., Brenner, K., Beke, D., et al.: Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. Anticancer Res., 2005, 25, 3607-3612. (Pubitemid 41105249)
34. Deftos, L. J., First, B. P.: Calcitonin as a drug. Ann. Intern. Med., 1981, 95, 192-197. (Pubitemid 11039830)
35. Wisneski, L. A.: Salmon calcitonin in the acute management of hypercalcemia. Calcif. Tissue Int., 1990, 46 (Suppl.), S26-S30. (Pubitemid 20047205)
36. Thiébaud, D., Jacquet, A. F., Burckhardt, P.: Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch. Intern. Med., 1990, 150, 2125-2128. (Pubitemid 20348364)
37. Warrell, R. P. Jr., Bockman, R. S., Coonley, C. J., et al.: Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J. Clin. Invest., 1984, 73, 1487-1490. (Pubitemid 14139545)
38. Warrell, R. P. Jr., Israel, R., Frisone, M., et al.: Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann. Intern. Med., 1988, 108, 669-674.
39. Cvitkovic, F., Armand, J. P., Tubiana-Hulin, M., et al.: Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J., 2006, 12, 47-53.
40. Koo, W. S., Jeon, D. S., Ahn, S. J., et al.: Calcium-free hemodialysis for the management of hypercalcemia. Nephron, 1996, 72, 424-428. (Pubitemid 26059574)
41. Trouvin, A. P., Goëb, V.: Receptor activator of nuclear factor-?B ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin. Interv. Aging, 2010, 5, 345-354.
42. Kearns, A. E., Khosla, S., Kostenuik, P. J.: Receptor activator of nuclear factor kappa-B ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev., 2008, 29, 155-192. (Pubitemid 351519689)
43. Lewiecki, E. M.: Denosumab update. Curr. Opin. Rheumatol., 2009, 21, 369-373.
44. Diel, I. J., et al.: Effect of denosumab treatment on prevention of hypercalcemia of malignancy in cancer patients with metastatic bone disease. European Multidisciplinary Cancer Congress ECCO-ESMO 2011, Abstract 3051.